INT J LAB HEMATOL:加拿大技术专家和病理学家对血液检查实践模式的调查结果

2019-02-01 MedSci MedSci原创

目前还没有一种关于血涂片通用的或被广泛接受的医师复核标准,也没有经报道的血涂片医师复核率标准。为了更好地了解加拿大各地不同机构进行血液检查的方式和原因,本研究进行了一项调查,以评估加拿大医生对血涂片审查的实践模式。

研究人员开发了一项15个问题调查问卷,并通过电子邮件发送给加拿大各地的24个学术的,大型社区和企业实验室。选择的中心包括加拿大的所有省份和大多数主要学术中心。24个中心中有20个作出回应。

结果显示,每天处理的所有CBC的百分比,医生对血涂片的评价的平均比率为4.1%(范围0.35-13%),并且每天制备的所有血膜的平均比例为28.8%(范围1.9-66.5%)。讨论可能影响医师复查率的因素数据,医生对医生血涂片复查率的百分比是否合理的偏好以及讨论了医生对血涂片检查的作用的看法。

该调查显示,加拿大医生对血液检查有不同的实践模式和意见。

原始出处:

David Barth MD, Results of a cross Canada survey of blood film review practice patterns by technologists and pathologists

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026219, encodeId=162e20262190c, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Tue Jul 16 17:57:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312598, encodeId=95d313125981a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317480, encodeId=df93131e480a9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473466, encodeId=6bd214e346665, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537887, encodeId=c107153e887ee, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026219, encodeId=162e20262190c, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Tue Jul 16 17:57:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312598, encodeId=95d313125981a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317480, encodeId=df93131e480a9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473466, encodeId=6bd214e346665, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537887, encodeId=c107153e887ee, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2026219, encodeId=162e20262190c, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Tue Jul 16 17:57:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312598, encodeId=95d313125981a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317480, encodeId=df93131e480a9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473466, encodeId=6bd214e346665, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537887, encodeId=c107153e887ee, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=2026219, encodeId=162e20262190c, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Tue Jul 16 17:57:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312598, encodeId=95d313125981a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317480, encodeId=df93131e480a9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473466, encodeId=6bd214e346665, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537887, encodeId=c107153e887ee, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 jktdtl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2026219, encodeId=162e20262190c, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Tue Jul 16 17:57:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312598, encodeId=95d313125981a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317480, encodeId=df93131e480a9, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473466, encodeId=6bd214e346665, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537887, encodeId=c107153e887ee, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Sun Feb 03 08:57:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]

相关资讯

Sci Rep:肺癌病理图像综合分析发现预测生存结局的肿瘤形态和边界特征

这项研究为肿瘤形态与患者预后之间的关联提供了新的见解。

ARCH PATHOL LAB MED:互联网论坛促进癌症登记员和病理学家之间的沟通?

癌症登记员应与病理学家密切合作,以确保符合报告标准。然而,许多登记员很少与病理学家接触,导致缺乏对其个人专业活动和发展的实时互动。随着癌症生物学变得越来越复杂, 为方便注册医生的个案管理,本研究开发了ATP(询问病理学家)论坛,以询问与肿瘤相关的问题,如术语、生物学、组织学分类、疾病程度、分子标记和预后因素。 所罗列的问题由ATP多学科监督委员会审核,该委员会由3名病理学家、4名癌症登

Int J Oral Max Surg: 成年人群第三磨牙的症状

本研究的目的是评估代表30岁及以上芬兰人群中第三磨牙的临床和影像学征象。

中国将打破医师执业证终生制 三大专业医师率先开展定期考核

    8月10日,第22届中国内镜医师大会在广东省中山市开幕,记者从卫生部内镜与微创医师定期考核专家委员会获悉,该委员会将首次启动全国医师终生定期统考制度,包括内镜微创、病理学、整形美容在内的三个专业将在全国率先开展定期考核。     近期在卫生部召开的“全国医师定期考核内镜与微创专业委员会成立暨第一次考试工作会议”上,内镜与微创医师

病理学(Pathology)词汇

病理学(Pathology)词汇pathology <病理学Pathology)> 病理学 acidophilic body <病理学Pathology)> 嗜酸小体 acute inflammation <病理学Pathology)> 急性炎症 acute proliferative glomerulonephritis, acute prol glom.rm